Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

646 articles

Research Review

Showing 1–4 of 4 articles · Keyword: protein Corona Clear keyword

Expert opinion on drug delivery2026ReviewDrug Delivery

1. Semi-randomized zwitterionic peptides: a breakthrough in drug delivery

Hernandez Pa, Moore Cj, Overby Ct, Benoit Dsw

Nanoparticle drug delivery systems (NP DDS) have transformed therapeutic delivery by improving drug stability, extending circulation time, and enabling targeted biodistribution. However, clinical translation remains limited by protein corona formation, immune recognition, and accelerated blood clearance following…

Read the article

Exploration (Beijing, China)2026ReviewDrug Delivery

2. Autonomous Nanomedicine: Closing the Biological Validation Gap

Lin Yj, Komperda I

Although nanomedicines offer advanced formulation control and physicochemical characterization, clinical translation has been limited. Delivery meta-analyses and late-stage attrition indicate biological validation is often a bottleneck. It must account for context-dependent processes such as protein corona formation…

Read the article

Expert opinion on drug delivery2026ReviewDrug Delivery

3. Apolipoproteins in nanoparticle-mediated brain drug delivery: promise, mechanisms, and misconceptions

Gelperina S, Wacker Mg

Apolipoprotein E (apoE) plays a context-dependent role in nanomedicine for central nervous system drug delivery. It can facilitate cerebral endothelial recognition and increase brain exposure in nanoparticle systems while simultaneously promoting hepatic uptake, challenging its traditional interpretation as a…

Read the article

Pharmaceutics2026ReviewDrug Delivery

4. Beyond Uptake in Cancer Lipid Nanomedicines: Linking Tumour Access, Intracellular Fate, and Molecular Action

Syed Hashim Sa

Clinical translation of lipid nanomedicines in oncology is limited by biological barriers and by an interpretive challenge: tumour accumulation and cellular uptake are often used as proxies for delivery even when pharmacologically competent cargo, meaning cargo capable of producing its intended molecular effect, has…

Read the article

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.